Opzelura (Ruxolitinib Cream) for Vitiligo: The Complete Patient Guide

Opzelura is the first medication ever approved by the FDA specifically for vitiligo repigmentation. That is a significant milestone after decades when patients were told there was nothing proven that worked. But “FDA-approved” is not the same as “works for everyone,” and the cost and access issues are real.

This is the complete picture.

What Opzelura is

Opzelura is the brand name for ruxolitinib cream 1.5%, made by Incyte. It is a topical JAK inhibitor — specifically, it blocks JAK1 and JAK2 enzymes that play a central role in the inflammatory signalling responsible for the immune attack on melanocytes in vitiligo.

In vitiligo, the JAK-STAT pathway (particularly IFN-γ/CXCL10 signalling) drives T-cell activity that destroys melanin-producing cells. Opzelura interrupts that signalling at the skin level. By reducing local immune activity, it allows surviving melanocytes — particularly those in hair follicles — to migrate back into depigmented patches.

Approved for: Non-segmental vitiligo in patients 12 years and older. Approval date: July 18, 2022 (FDA). Formulation: 1.5% cream, applied twice daily.

Who it works best for

The pivotal trials (TRuE-V1 and TRuE-V2, both published in the New England Journal of Medicine in 2022) showed clear superiority over vehicle cream. But the results were not uniform:

Better results in:

Facial vitiligo — the face responds faster and more completely than the body. At 52 weeks, approximately 30% of facial patients achieved 75% or greater facial repigmentation (F-VASI75).
Non-segmental vitiligo — the autoimmune type, which is the approved indication
Recently depigmented patches — areas where melanocytes have been gone for less than 5 years tend to respond better than long-standing patches
Patches without leukotrichia (white hair within the patch) — white hairs indicate deeper melanocyte reservoir loss, which predicts poorer response

Weaker results in:

Body vitiligo — body patches respond more slowly and to a lesser degree than facial
Segmental vitiligo — the mechanism is different, and the drug is not approved for this type
Long-standing patches with complete melanocyte depletion — if there is no melanocyte reservoir to reactivate, repigmentation cannot occur
Very large body surface areas — the approved BSA for application is limited; the practical coverage challenge affects widespread cases

Realistic timelines

The trials ran to 52 weeks (one year). Here is the approximate timeline:

Weeks 4–8: Some patients see faint pink blush at patch edges — early sign of follicular repigmentation starting
Weeks 12–24: Visible repigmentation in responders, particularly on the face
Week 24: First real assessment point. If no response at all by 24 weeks, the current guidance suggests reconsidering
Week 52: Full-year response data. Facial F-VASI75 in ~30% of patients; body T-VASI responses are more modest

What this means practically: Do not expect dramatic change in the first 2 months. Repigmentation from follicular melanocyte migration is slow — small dots appear at follicle openings and slowly merge. Patience matters more than almost any other factor.

How to use it correctly

Application technique affects outcomes:

Twice daily application — morning and evening. Consistency matters more than quantity.
Thin layer — rub in gently until absorbed. Do not use large amounts.
Sun exposure after application — natural daylight exposure after applying enhances response. This is not accidental: the combination of JAK inhibition and UV stimulation is synergistic. Apply in the morning before spending time outdoors.
Do not wash off immediately — let it absorb for at least 20–30 minutes before washing the area
Approved BSA limit — apply to affected vitiligo patches only, up to 10% body surface area (roughly the area of one arm). Using on larger areas is outside the approved indication.

Combining Opzelura with phototherapy

The combination of Opzelura + narrowband UVB phototherapy is widely discussed in the vitiligo community and appears in the literature as a more potent combination than either alone. The logic:

NbUVB stimulates melanocyte migration and proliferation
Opzelura suppresses the immune attack on new melanocytes
Together, they address both the supply problem (new cells) and the destruction problem (immune suppression)

Several studies and real-world case series show faster and more complete repigmentation with combination versus monotherapy. If you have access to a home NbUVB unit, this combination is worth discussing with your dermatologist. For more on home phototherapy: Narrowband UVB at Home.

Side effects

Because Opzelura is topical, systemic absorption is minimal — which makes its safety profile much more favourable than oral JAK inhibitors.

Common (reported in trials):

Application site acne — the most common, particularly on the face. Usually manageable.
Application site pruritus (itching) — generally mild
Nasopharyngitis — mild upper respiratory symptoms, likely related to very low systemic absorption

The oral JAK inhibitor class warnings (MACE, malignancy, thrombosis, serious infections) were applied to topical ruxolitinib by the FDA as a class-wide label update, not based on safety signals in the vitiligo trials themselves. The actual clinical risk from topical application at the approved BSA is very low, but it is worth discussing with your dermatologist if you have cardiovascular risk factors or a history of malignancy.

Do not use on infected skin. The immune-suppressing effect locally can reduce the skin’s normal defences against bacteria and fungi at the application site.

Cost and insurance

Opzelura is expensive — approximately $2,000–$2,500 per 60g tube at list price in the US. Most patients need one tube per month for facial vitiligo, more for body areas.

Insurance: Prior authorisation is required by most insurers. Denials on first submission are common. If denied, the appeal process works — see the full guide: How to Appeal an Opzelura Insurance Denial.

Patient assistance:

IncyteCARES (incytecares.com) — manufacturer’s programme for uninsured or underinsured patients. Can provide the medication free or at very low cost.
Copay cards — available for commercially insured patients with a copay card reducing monthly costs significantly. Ask your dermatologist’s office or check the Incyte website.
Outside the US — Opzelura has received approval in several countries. Availability, coverage, and cost vary significantly. United Kingdom: Opzelura (ruxolitinib cream) received NHS approval in February 2026, making it available to UK patients through specialist dermatology referral. This is a significant development - prior to this, UK patients had no NHS-funded option for repigmentation. Access is through secondary care (a dermatologist, not a GP), and referral criteria will vary by trust. Private prescription is also available in the UK, though at significant cost. Outside the UK, access in European countries is through specialist referral only, and coverage varies.

What to do if it stops working

Some patients experience initial repigmentation that plateaus or partially reverses when they stop treatment. Key points:

Opzelura suppresses the immune attack — when you stop, the immune system may resume activity
Some patients maintain their repigmentation after stopping; others see slow reversal over months
Current evidence suggests treating as a long-term management tool for active disease rather than a curative course
If plateau occurs after good initial response, the combination with NbUVB may restart progress

Opzelura vs upadacitinib — what’s coming next

AbbVie submitted upadacitinib (Rinvoq, an oral JAK inhibitor) for FDA approval in vitiligo in February 2026. When approved, it will offer an oral systemic option for patients whose vitiligo is too widespread for topical treatment. For now, Opzelura remains the only approved option. For more: Upadacitinib for Vitiligo — What We Know So Far.